Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04805892 · ClinicalTrials.gov registry record · NA
Study Utilizing BIOZEK COVID-19 Antigen Rapid Test.
A NA study, sponsored by Mach-E B.V..
- Completed
- Registry status
- NA
- Development phase
- 84
- Enrollment target
NCT04805892 is a NA study that has completed, run by Mach-E B.V.. The registered enrollment target is 84 participants.
The verdict
NCT04805892, a NA study, has completed, sponsored by Mach-E B.V..
- COMPLETED
- Registry status
- NA
- Development phase
- 84 participants
- Enrollment target
Study Summary
This is a research study to evaluate the Sensitivity and Specificity of BIOZEK COVID-19 Antigen Rapid Test on samples collected by a healthcare professional versus self-collection; and to perform analysis to compare results. In addition, to obtain RT-PCR test results, performed prior to enrollment, and compare all three results.
Interventions
- DIAGNOSTIC_TEST BIOZEK COVID-19 Antigen Rapid Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2021-03-17 |
| Est. Completion | 2022-02-23 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04805892
The ClinicalTrials.gov registry entry for NCT04805892 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mach-E B.V., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BIOZEK COVID-19 Antigen Rapid Test is the first listed.
NCT04805892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04805892 about?
NCT04805892 is a clinical study titled "Study Utilizing BIOZEK COVID-19 Antigen Rapid Test.". This is a research study to evaluate the Sensitivity and Specificity of BIOZEK COVID-19 Antigen Rapid Test on samples collected by a healthcare professional versus self-collection; and to perform analysis to compare results. In addition, to obtain RT-PCR test results, performed prior to enrollment, ...
What is the current status of trial NCT04805892?
This trial is currently completed. It is a NA study. The enrollment target is 84 participants. The study started on 2021-03-17. Estimated completion is 2022-02-23.
What interventions are being tested in trial NCT04805892?
The interventions under investigation include: BIOZEK COVID-19 Antigen Rapid Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04805892?
This trial is sponsored by Mach-E B.V., which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.